82 FR 2280 - Schedules of Controlled Substances: Temporary Placement of Six Synthetic Cannabinoids (5F-ADB, 5F-AMB, 5F-APINACA, ADB-FUBINACA, MDMB-CHMICA and MDMB-FUBINACA) Into Schedule I
DEPARTMENT OF JUSTICE
Drug Enforcement Administration Federal Register Volume 82, Issue 5 (January 9, 2017)
Drug Enforcement Administration
Federal Register Volume 82, Issue 5 (January 9, 2017)
| Page Range | 2280-2284 | |
| FR Document | 2017-00275 |
[Federal Register Volume 82, Number 5 (Monday, January 9, 2017)] [Proposed Rules] [Pages 2280-2284] From the Federal Register Online [www.thefederalregister.org] [FR Doc No: 2017-00275] ======================================================================= ----------------------------------------------------------------------- DEPARTMENT OF JUSTICE Drug Enforcement Administration 21 CFR Part 1308 [Docket No. DEA-446] Schedules of Controlled Substances: Temporary Placement of Six Synthetic Cannabinoids (5F-ADB, 5F-AMB, 5F-APINACA, ADB-FUBINACA, MDMB- CHMICA and MDMB-FUBINACA) Into Schedule I AGENCY: Drug Enforcement Administration, Department of Justice. ACTION: Notice of intent. ----------------------------------------------------------------------- SUMMARY: The Administrator of the Drug Enforcement Administration is issuing this notice of intent to temporarily schedule six synthetic cannabinoids: Methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)- 3,3-dimethylbutanoate [5F-ADB; 5F-MDMB-PINACA]; methyl 2-(1-(5- fluoropentyl)-1H-indazole-3-carboxamido)-3-methylbutanoate [5F-AMB]; N- (adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide [5F- APINACA, 5F-AKB48]; N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4- fluorobenzyl)-1H-indazole-3-carboxamide [ADB-FUBINACA]; methyl 2-(1- (cyclohexylmethyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate [MDMB-CHMICA, MMB-CHMINACA] and methyl 2-(1-(4-fluorobenzyl)-1H- indazole-3-carboxamido)-3,3-dimethylbutanoate [MDMB-FUBINACA], into schedule I pursuant to the temporary scheduling provisions of the Controlled Substances Act (CSA). This action is based on a finding by the Administrator that the placement of these synthetic cannabinoids into schedule I of the Controlled Substances Act is necessary to avoid an imminent hazard to the public safety. Any final order will impose the administrative, civil, and criminal sanctions and regulatory controls applicable to schedule I substances under the Controlled Substances Act on the manufacture, distribution, possession, importation, exportation of, and research and conduct with, instructional activities of these synthetic cannabinoids. [[Page 2281]] DATES: January 9, 2017. FOR FURTHER INFORMATION CONTACT: Michael J. Lewis, Office of Diversion Control, Drug Enforcement Administration; Mailing Address: 8701 Morrissette Drive, Springfield, Virginia 22152; Telephone: (202) 598- 6812. SUPPLEMENTARY INFORMATION: Any final order will be published in the Federal Register and may not be effective prior to February 8, 2017. Legal Authority The Drug Enforcement Administration (DEA) implements and enforces titles II and III of the Comprehensive Drug Abuse Prevention and Control Act of 1970, as amended. 21 U.S.C. 801-971. Titles II and III are referred to as the ``Controlled Substances Act'' and the ``Controlled Substances Import and Export Act,'' respectively, and are collectively referred to as the ``Controlled Substances Act'' or the ``CSA'' for the purpose of this action. The DEA publishes the implementing regulations for these statutes in title 21 of the Code of Federal Regulations (CFR), chapter II. The CSA and its implementing regulations are designed to prevent, detect, and eliminate the diversion of controlled substances and listed chemicals into the illicit market while providing for the legitimate medical, scientific, research, and industrial needs of the United States. Controlled substances have the potential for abuse and dependence and are controlled to protect the public health and safety. Under the CSA, every controlled substance is classified into one of five schedules based upon its potential for abuse, its currently accepted medical use in treatment in the United States, and the degree of dependence the drug or other substance may cause. 21 U.S.C. 812. The initial schedules of controlled substances established by Congress are found at 21 U.S.C. 812(c), and the current list of all scheduled substances is published at 21 CFR part 1308. Section 201 of the CSA, 21 U.S.C. 811, provides the Attorney General with the authority to temporarily place a substance into schedule I of the CSA for two years without regard to the requirements of 21 U.S.C. 811(b) if she finds that such action is necessary to avoid an imminent hazard to the public safety. 21 U.S.C. 811(h)(1). In addition, if proceedings to control a substance are initiated under 21 U.S.C. 811(a)(1), the Attorney General may extend the temporary scheduling for up to one year. 21 U.S.C. 811(h)(2). Where the necessary findings are made, a substance may be temporarily scheduled if it is not listed in any other schedule under section 202 of the CSA, 21 U.S.C. 812, or if there is no exemption or approval in effect for the substance under section 505 of the Federal Food, Drug, and Cosmetic Act (FDCA), 21 U.S.C. 355. 21 U.S.C. 811(h)(1); 21 CFR part 1308. The Attorney General has delegated scheduling authority under 21 U.S.C. 811 to the Administrator of the DEA. 28 CFR 0.100. Background Section 201(h)(4) of the CSA 21 U.S.C. 811(h)(4), requires the Administrator to notify the Secretary of the Department of Health and Human Services (HHS) of any intention to temporarily place a substance into schedule I of the CSA.\1\ The Acting Administrator transmitted notice of his intent to place 5F-ADB, 5F-AMB, 5F-APINACA, ADB-FUBINACA, MDMB-CHMICA and MDMB-FUBINACA in schedule I on a temporary basis to the Assistant Secretary by letter dated April 22, 2016. The Assistant Secretary responded to this notice by letter dated May 2, 2016, and advised that based on a review by the Food and Drug Administration (FDA), there were no investigational new drug applications or approved new drug applications for 5F-ADB, 5F-AMB, 5F-APINACA, ADB-FUBINACA, MDMB-CHMICA or MDMB-FUBINACA. The Assistant Secretary also stated that the HHS had no objection to the temporary placement of 5F-ADB, 5F-AMB, 5F-APINACA, ADB-FUBINACA, MDMB-CHMICA or MDMB-FUBINACA into schedule I of the CSA. 5F-ADB, 5F-AMB, 5F-APINACA, ADB-FUBINACA, MDMB-CHMICA or MDMB-FUBINACA are not currently listed in any schedule under the CSA. --------------------------------------------------------------------------- \1\ As discussed in a memorandum of understanding entered into by the Food and Drug Administration (FDA) and the National Institute on Drug Abuse (NIDA), the FDA acts as the lead agency within the Department of Health and Human Service (HHS) in carrying out the Secretary's scheduling responsibilities under the CSA, with the concurrence of NIDA. 50 FR 9518, Mar. 8, 1985. The Secretary of the HHS has delegated to the Assistant Secretary for Health of the HHS the authority to make domestic drug scheduling recommendations. 58 FR 35460, July 1, 1993. --------------------------------------------------------------------------- To find that placing a substance temporarily into schedule I of the CSA is necessary to avoid an imminent hazard to the public safety, the Administrator is required to consider three of the eight factors set forth in 21 U.S.C. 811(c): The substance's history and current pattern of abuse; the scope, duration and significance of abuse; and what, if any, risk there is to the public health. 21 U.S.C. 811(h)(3). Consideration of these factors includes actual abuse, diversion from legitimate channels, and clandestine importation, manufacture, or distribution. 21 U.S.C. 811(h)(3). A substance meeting the statutory requirements for temporary scheduling may only be placed in schedule I. 21 U.S.C. 811(h)(1). Substances in schedule I are those that have a high potential for abuse, no currently accepted medical use in treatment in the United States, and a lack of accepted safety for use under medical supervision. 21 U.S.C. 812(b)(1). 5F-ADB, 5F-AMB, 5F-APINACA, ADB-FUBINACA, MDMB-CHMICA and MDMB-FUBINACA Available data and information for 5F-ADB, 5F-AMB, 5F-APINACA, ADB- FUBINACA, MDMB-CHMICA and MDMB-FUBINACA indicate that these synthetic cannabinoids (SCs) have a high potential for abuse, no currently accepted medical use in treatment in the United States, and a lack of accepted safety for use under medical supervision. Synthetic Cannabinoids SCs are substances synthesized in laboratories that mimic the biological effects of delta-9-tetrahydrocannabinol (THC), the main psychoactive ingredient in marijuana. It is believed that SCs were first introduced on the designer drug market in several European countries as ``herbal incense'' before the initial encounter in the United States by U.S. Customs and Border Protection (CBP) in November 2008. From 2009 to the present, misuse and abuse of SCs has increased in the United States with law enforcement encounters describing SCs applied onto plant material and in designer drug products intended for human consumption. It has been demonstrated that the substances and the associated designer drug products are abused for their psychoactive properties. With many generations of SCs having been encountered since 2009, 5F-ADB, 5F-AMB, 5F-APINACA, ADB-FUBINACA, MDMB-CHMICA and MDMB- FUBINACA are some of the latest, and the abuse of these substances is negatively impacting communities. As observed by the DEA and CBP, SCs originate from foreign sources, such as China. Bulk powder substances are smuggled via common carrier into the United States and find their way to clandestine designer drug product manufacturing operations located in residential neighborhoods, garages, warehouses, and other similar destinations throughout the country. According to online discussion boards and law enforcement encounters, [[Page 2282]] applying by spraying or mixing the SCs with plant material provides a vehicle for the most common route of administration--smoking (using a pipe, a water pipe, or rolling the drug-laced plant material in cigarette papers). 5F-ADB, 5F-AMB, 5F-APINACA, ADB-FUBINACA, MDMB-CHMICA, and MDMB- FUBINACA have no accepted medical use in the United States. Use of these specific SCs has been reported to result in adverse effects in humans including deaths (see 3-Factor document in ``Supporting and Related Material'' section). Use of other SCs has resulted in signs of addiction and withdrawal, and based on the similar pharmacological profile of these six substances, it is believed that there will be similar observed adverse effects. 5F-ADB, 5F-AMB, 5F-APINACA, ADB-FUBINACA, MDMB-CHMICA and MDMB- FUBINACA are SCs that have pharmacological effects similar to the schedule I hallucinogen delta-[Delta]-tetrahydrocannabinol (THC) and temporarily and permanently controlled schedule I synthetic cannabinoid substances. In addition, the misuse of 5F-ADB, 5F-AMB, 5F-APINACA, ADB- FUBINACA, MDMB-CHMICA and/or MDMB-FUBINACA have been associated with either overdoses requiring emergency medical intervention or death (see factor 6). With no approved medical use and limited safety or toxicological information, 5F-ADB, 5F-AMB, 5F-APINACA, ADB-FUBINACA, MDMB-CHMICA and MDMB-FUBINACA have emerged on the designer drug market, and the abuse of these substances for their psychoactive properties is concerning. The DEA's analysis is available in its entirety under ``Supporting and Related Material'' of the public docket for this action at www.regulations.gov under docket number DEA-443. Factor 4. History and Current Pattern of Abuse Synthetic cannabinoids have been developed over the last 30 years as tools for investigating the endocannabinoid system (e.g., determining CB1 and CB2 receptor activity). The first encounter of SCs within the United States occurred in November 2008 by CBP. Since then the popularity of SCs and their associated products has increased steadily as evidenced by law enforcement seizures, public health information, and media reports. 5F-ADB, 5F-AMB, 5F-APINACA, ADB- FUBINACA, MDMB-CHMICA and MDMB-FUBINACA are SCs that have been recently encountered (see ``Supporting and Related Material,'' Factor 5). Multiple overdoses involving emergency medical intervention or deaths have been associated with 5F-ADB, 5F-AMB, 5F-APINACA, ADB-FUBINACA, MDMB-CHMICA and MDMB-FUBINACA. Research and clinical reports have demonstrated that SCs are applied onto plant material so that the material may be smoked as users attempt to obtain a euphoric and/or psychoactive ``high,'' believed to be similar to marijuana. Data gathered from published studies, supplemented by discussions on Internet discussion Web sites, demonstrate that these products are being abused mainly by smoking for their psychoactive properties. The adulterated products are marketed as ``legal'' alternatives to marijuana. In recent overdoses, 5F-ADB, 5F- AMB, 5F-APINACA, ADB-FUBINACA, MDMB-CHMICA and MDMB-FUBINACA have been shown to be applied onto plant material, similar to the SCs that have been previously available. Law enforcement personnel have encountered various application methods including buckets or cement mixers in which plant material and one or more SCs (including 5F-ADB, 5F-AMB, 5F-APINACA, ADB-FUBINACA, MDMB-CHMICA and/or MDMB-FUBINACA) are mixed together, as well as large areas where the plant material is spread out so that a dissolved SC mixture can be applied directly. Once mixed, the SC plant material is then allowed to dry before manufacturers package the product for distribution, ignoring any control mechanisms to prevent contamination or to ensure a consistent, uniform concentration of the substance in each package. Adverse health consequences may also occur from directly ingesting the substance(s) during the manufacturing process. 5F-ADB, 5F-AMB, 5F-APINACA, ADB-FUBINACA, MDMB-CHMICA and MDMB-FUBINACA, similar to other SCs, have been encountered in form of dried leaves or herbal blends. The designer drug products laced with SCs, including 5F-ADB, 5F- AMB, 5F-APINACA, ADB-FUBINACA, MDMB-CHMICA and MDMB-FUBINACA, are often sold under the guise of ``herbal incense'' or ``potpourri,'' use various product names, and are routinely labeled ``not for human consumption.'' Additionally, these products are marketed as a ``legal high'' or ``legal alternative to marijuana'' and are readily available over the Internet, in head shops, or sold in convenience stores. There is an incorrect assumption that these products are safe, that they are a synthetic form of marijuana, and that labeling these products as ``not for human consumption'' is a legal defense to criminal prosecution. A major concern, as reiterated by public health officials and medical professionals, is the targeting and direct marketing of SCs and SC-containing products to adolescents and youth. This is supported by law enforcement encounters and reports from emergency departments; however, all age groups have been reported by media as abusing these substances and related products. Individuals, including minors, are purchasing SCs from Internet Web sites, gas stations, convenience stores, and head shops. Factor 5. Scope, Duration and Significance of Abuse SCs, including 5F-ADB, 5F-AMB, 5F-APINACA, ADB-FUBINACA, MDMB- CHMICA and MDMB-FUBINACA, continue to be encountered on the illicit market regardless of scheduling actions that attempt to safeguard the public from the adverse effects and safety issues associated with these substances. Numerous substances are encountered each month, differing only by small modifications intended to avoid prosecution while maintaining the pharmacological effects. Law enforcement and health care professionals continue to report abuse of these substances and their associated products. As described by the National Institute on Drug Abuse (NIDA), many substances being encountered in the illicit market, specifically SCs, have been available for years but have reentered the marketplace due to a renewed popularity. The threat of serious injury to the individual following the ingestion of 5F-ADB, 5F-AMB, 5F-APINACA, ADB-FUBINACA, MDMB-CHMICA and MDMB-FUBINACA and other SCs persists. Numerous calls have been received by poison centers regarding the abuse of products potentially laced with SCs that have resulted in visits to emergency departments. Law enforcement continues to encounter novel SCs on the illicit market, including 5F-ADB, 5F-AMB, 5F-APINACA, ADB-FUBINACA, MDMB-CHMICA and MDMB-FUBINACA (see factor 5 in ``Supporting and Related Material''). The following information details information obtained through NFLIS \2\ (queried on November 7, 2016), [[Page 2283]] including dates of first encounter, exhibits/reports, and locations. --------------------------------------------------------------------------- \2\ The National Forensic Laboratory Information System (NFLIS) is a national drug forensic laboratory reporting system that systematically collects results from drug chemistry analyses conducted by state and local forensic laboratories in the United States. --------------------------------------------------------------------------- 5F-ADB: NFLIS--2,311 reports, first encountered in September 2014, locations include: Arizona, Arkansas, California, Florida, Georgia, Idaho, Indiana, Iowa, Kansas, Kentucky, Louisiana, Missouri, New Jersey, North Dakota, Ohio, Oklahoma, Pennsylvania, South Carolina, Texas, Virginia, and Wisconsin. 5F-AMB: NFLIS--3,349 reports, first encountered in January 2014, locations include: Arizona, Arkansas, California, Colorado, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maryland, Massachusetts, Minnesota, Mississippi, Missouri, Nebraska, New Hampshire, New Jersey, New Mexico, New York, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, South Carolina, Tennessee, Texas, Utah, Virginia, Wisconsin, and Wyoming. 5F-APINACA: NFLIS--1,936 reports, first encountered in August 2012, locations include: Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maryland, Minnesota, Mississippi, Missouri, Nebraska, New Hampshire, New Jersey, North Dakota, Ohio, Oklahoma, Pennsylvania, Puerto Rico, South Carolina, Tennessee, Texas, Utah, Virginia, West Virginia, Wisconsin, and Wyoming. ADB-FUBINACA: NFLIS--942 reports, first encountered in March 2014, locations include: Arkansas, California, Colorado, Florida, Georgia, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maryland, Mississippi, Missouri, New Jersey, New Mexico, New York, North Dakota, Ohio, Pennsylvania, Texas, Utah, Virginia, and Wyoming. MDMB-CHMICA: NFLIS--227 reports, first encountered in March 2015, locations include: Arkansas, Georgia, Indiana, Kentucky, Louisiana, Nevada, Ohio, Oklahoma, South Carolina, and Texas. MDMB-FUBINACA: NFLIS--507 reports, first encountered in July 2015, locations include: Arkansas, California, Colorado, Connecticut, Georgia, Idaho, Indiana, Kansas, Kentucky, Louisiana, Missouri, Nevada, New Jersey, New Mexico, North Dakota, Ohio, Oklahoma, Pennsylvania, Texas, Virginia, Wisconsin, and West Virginia. Factor 6. What, if Any, Risk There Is to the Public Health 5F-ADB, 5F-AMB, 5F-APINACA, ADB-FUBINACA, MDMB-CHMICA and MDMB- FUBINACA have all been identified in overdose and/or cases involving death attributed to their abuse. Adverse health effects reported from these incidents involving 5F-ADB, 5F-AMB, 5F-APINACA, ADB-FUBINACA, MDMB-CHMICA and/or MDMB-FUBINACA have included: nausea, persistent vomiting, agitation, altered mental status, seizures, convulsions, loss of consciousness and/or cardio toxicity. Large clusters of overdoses requiring medical care have been reported involving 5F-AMB, MDMB- FUBINACA, MDMB-CHMICA and 5F-ADB. Reported deaths involving these SCs have included 5F-ADB (8); 5F-AMB (6); 5F-APINACA (1); ADB-FUBINACA (2); MDMB-CHMICA (4), European Monitoring Centre for Drugs and Drug Addiction has reported an additional 12 deaths involving MDMB-CHMICA; and MDMB-FUBINACA (1) (see factor 6 in ``Supporting and Related Material''). Finding of Necessity of Schedule I Placement To Avoid Imminent Hazard to Public Safety In accordance with 21 U.S.C. 811(h)(3), based on the available data and information summarized above, the continued uncontrolled manufacture, distribution, importation, exportation, conduct of research and chemical analysis, possession, and abuse of 5F-ADB, 5F- AMB, 5F-APINACA, ADB-FUBINACA, MDMB-CHMICA and MDMB-FUBINACA pose an imminent hazard to the public safety. The DEA is not aware of any currently accepted medical uses for these substances in the United States. A substance meeting the statutory requirements for temporary scheduling, 21 U.S.C. 811(h)(1), may only be placed in schedule I. Substances in schedule I are those that have a high potential for abuse, no currently accepted medical use in treatment in the United States, and a lack of accepted safety for use under medical supervision. Available data and information for 5F-ADB, 5F-AMB, 5F- APINACA, ADB-FUBINACA, MDMB-CHMICA and MDMB-FUBINACA indicate that these SCs have a high potential for abuse, no currently accepted medical use in treatment in the United States, and a lack of accepted safety for use under medical supervision. As required by section 201(h)(4) of the CSA, 21 U.S.C. 811(h)(4), the Administrator, through a letter dated April 22, 2016, notified the Assistant Secretary of the DEA's intention to temporarily place these six substances in schedule I. Conclusion This notice of intent initiates a temporary scheduling action and provides the 30-day notice pursuant to section 201(h) of the CSA, 21 U.S.C. 811(h). In accordance with the provisions of section 201(h) of the CSA, 21 U.S.C. 811(h), the Administrator considered available data and information, herein sets forth the grounds for his determination that it is necessary to temporarily schedule methyl 2-(1-(5- fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate [5F-ADB; 5F-MDMB-PINACA]; methyl 2-(1-(5-fluoropentyl)-1H-indazole-3- carboxamido)-3-methylbutanoate [5F-AMB]; N-(adamantan-1-yl)-1-(5- fluoropentyl)-1H-indazole-3-carboxamide [5F-APINACA, 5F-AKB48]; N-(1- amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3- carboxamide [ADB-FUBINACA]; methyl 2-(1-(cyclohexylmethyl)-1H-indole-3- carboxamido)-3,3-dimethylbutanoate [MDMB-CHMICA, MMB-CHMINACA] and methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3,3- dimethylbutanoate [MDMB-FUBINACA] in schedule I of the CSA, and finds that the placement of these substances into schedule I of the CSA on a temporary basis is necessary to avoid an imminent hazard to the public safety. Because the Administrator hereby finds that it is necessary to temporarily place these SCs into schedule I to avoid an imminent hazard to the public safety, any subsequent final order temporarily scheduling these substances will be effective on the date of publication in the Federal Register, and will be in effect for a period of two years, with a possible extension of one additional year, pending completion of the regular (permanent) scheduling process. 21 U.S.C. 811(h)(1) and (2). It is the intention of the Administrator to issue such a final order as soon as possible after the expiration of 30 days from the date of publication of this notice. 5F-ADB, 5F-AMB, 5F-APINACA, ADB-FUBINACA, MDMB-CHMICA and MDMB-FUBINACA will then be subject to the regulatory controls and administrative, civil, and criminal sanctions applicable to the manufacture, distribution, importation, exportation, research, conduct of instructional activities, and chemical analysis and possession of a schedule I controlled substance. The CSA sets forth specific criteria for scheduling a drug or other substance. Regular scheduling actions in accordance with 21 U.S.C. 811(a) are subject to formal rulemaking procedures [[Page 2284]] done ``on the record after opportunity for a hearing'' conducted pursuant to the provisions of 5 U.S.C. 556 and 557. 21 U.S.C. 811. The regular scheduling process of formal rulemaking affords interested parties with appropriate process and the government with any additional relevant information needed to make a determination. Final decisions that conclude the regular scheduling process of formal rulemaking are subject to judicial review. 21 U.S.C. 877. Temporary scheduling orders are not subject to judicial review. 21 U.S.C. 811(h)(6). Regulatory Matters Section 201(h) of the CSA, 21 U.S.C. 811(h), provides for an expedited temporary scheduling action where such action is necessary to avoid an imminent hazard to the public safety. As provided in this subsection, the Attorney General may, by order, schedule a substance in schedule I on a temporary basis. Such an order may not be issued before the expiration of 30 days from (1) the publication of a notice in the Federal Register of the intention to issue such order and the grounds upon which such order is to be issued, and (2) the date that notice of the proposed temporary scheduling order is transmitted to the Assistant Secretary. 21 U.S.C. 811(h)(1). Inasmuch as section 201(h) of the CSA directs that temporary scheduling actions be issued by order and sets forth the procedures by which such orders are to be issued, the DEA believes that the notice and comment requirements of section 553 of the Administrative Procedure Act (APA), 5 U.S.C. 553, do not apply to this notice of intent. In the alternative, even assuming that this notice of intent might be subject to section 553 of the APA, the Administrator finds that there is good cause to forgo the notice and comment requirements of section 553, as any further delays in the process for issuance of temporary scheduling orders would be impracticable and contrary to the public interest in view of the manifest urgency to avoid an imminent hazard to the public safety. Although the DEA believes this notice of intent to issue a temporary scheduling order is not subject to the notice and comment requirements of section 553 of the APA, the DEA notes that in accordance with 21 U.S.C. 811(h)(4), the Administrator will take into consideration any comments submitted by the Assistant Secretary with regard to the proposed temporary scheduling order. Further, the DEA believes that this temporary scheduling action is not a ``rule'' as defined by 5 U.S.C. 601(2), and, accordingly, is not subject to the requirements of the Regulatory Flexibility Act (RFA). The requirements for the preparation of an initial regulatory flexibility analysis in 5 U.S.C. 603(a) are not applicable where, as here, the DEA is not required by section 553 of the APA or any other law to publish a general notice of proposed rulemaking. Additionally, this action is not a significant regulatory action as defined by Executive Order 12866 (Regulatory Planning and Review), section 3(f), and, accordingly, this action has not been reviewed by the Office of Management and Budget. This action will not have substantial direct effects on the States, on the relationship between the national government and the States, or on the distribution of power and responsibilities among the various levels of government. Therefore, in accordance with Executive Order 13132 (Federalism) it is determined that this action does not have sufficient federalism implications to warrant the preparation of a Federalism Assessment. List of Subjects in 21 CFR Part 1308 Administrative practice and procedure, Drug traffic control, Reporting and recordkeeping requirements. For the reasons set out above, the DEA proposes to amend 21 CFR part 1308 as follows: PART 1308--SCHEDULES OF CONTROLLED SUBSTANCES 0 1. The authority citation for part 1308 continues to read as follows: Authority: 21 U.S.C. 811, 812, 871(b), unless otherwise noted. 0 2. In Sec. 1308.11, add paragraph (h)(23) through (28) to read as follows: Sec. 1308.11 Schedule I * * * * * (h) * * * ------------------------------------------------------------------------ ------------------------------------------------------------------------ (23) methyl 2-(1-(5-fluoropentyl)-1H-indazole-3- (7034) carboxamido)-3,3-dimethylbutanoate, its optical, positional, and geometric isomers, salts and salts of isomers (Other names: 5F-ADB; 5F-MDMB-PINACA)............. (24) methyl 2-(1-(5-fluoropentyl)-1H-indazole-3- (7033) carboxamido)-3-methylbutanoate, its optical, positional, and geometric isomers, salts and salts of isomers (Other names: 5F-AMB)............................................ (25) N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3- (7049) carboxamide, its optical, positional, and geometric isomers, salts and salts of isomers (Other names: 5F- APINACA, 5F-AKB48)........................................ (26) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4- (7010) fluorobenzyl)-1H-indazole-3-carboxamide, its optical, positional, and geometric isomers, salts and salts of isomers (Other names: ADB-FUBINACA)....................... (27) methyl 2-(1-(cyclohexylmethyl)-1H-indole-3- (7042) carboxamido)-3,3-dimethylbutanoate, its optical, positional, and geometric isomers, salts and salts of isomers (Other names: MDMB-CHMICA, MMB-CHMINACA).......... (28) methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3- (7020) carboxamido)-3,3-dimethylbutanoate, its optical, positional, and geometric isomers, salts and salts of isomers (Other names: MDMB-FUBINACA)...................... ------------------------------------------------------------------------ * * * * * Dated: December 13, 2016. Chuck Rosenberg, Acting Administrator. [FR Doc. 2017-00275 Filed 1-6-17; 8:45 am] BILLING CODE 4410-09-P
![2280 Federal Register / Vol. 82, No. 5 / Monday, January 9, 2017 / Proposed Rules
Article I: Effect of Designation underwater cultural sites in and around the Article VI. Alteration of This Designation
The NMSA authorizes the issuance of such Wisconsin-Lake Michigan National Marine The terms of designation may be modified
regulations as are necessary and reasonable Sanctuary possess exceptional historical, only by the same procedures by which the
to implement the designation, including archaeological and recreational value. original designation is made, including
managing and protecting the historical Article IV: Scope of Regulations public meetings, consultation according to
resources and recreational, research, and the NMSA.
Section 1. Activities Subject to Regulation.
educational qualities of the Wisconsin-Lake
The following activities are subject to [FR Doc. 2016–31741 Filed 1–6–17; 8:45 am]
Michigan National Marine Sanctuary (the
regulation, including prohibition, to the BILLING CODE 03510–NK–P
‘‘Sanctuary’’). Section 1 of Article IV of this
extent necessary and reasonable to ensure the
Designation Document lists those activities
protection and management of the historical
that may have to be regulated on the effective resources and recreational, research and
date of designation, or at some later date, in educational qualities of the area: DEPARTMENT OF JUSTICE
order to protect Sanctuary resources and a. Damaging sanctuary resources.
qualities. Listing an activity does not b. Using grappling hooks and anchors at Drug Enforcement Administration
necessarily mean that it will be regulated; shipwreck sites.
however, if an activity is not listed it may not c. Interfering with, obstructing, delaying or 21 CFR Part 1308
be regulated, except on an emergency basis, preventing an investigation, search, seizure
unless Section 1 of Article IV is amended by or disposition of seized property in [Docket No. DEA–446]
the same procedures by which the original connection with enforcement of the Act or
Sanctuary designation was made. any regulation issued under the Act. Schedules of Controlled Substances:
d. Reporting shipwreck discoveries and Temporary Placement of Six Synthetic
Article II: Description of the Area
locations to the sanctuary. Cannabinoids (5F-ADB, 5F-AMB, 5F-
The Wisconsin-Lake Michigan National APINACA, ADB-FUBINACA, MDMB-
Section 2. Emergencies. Where necessary
Marine Sanctuary consists of an area of
to prevent or minimize the destruction of, CHMICA and MDMB-FUBINACA) Into
approximately 812 square nautical miles
loss of, or injury to a Sanctuary resource or Schedule I
(nmi2) (1,075 sq. mi) of Lake Michigan
quality; or minimize the imminent risk of
waters within the state of Wisconsin and the AGENCY: Drug Enforcement
such destruction, loss, or injury, any activity,
submerged lands thereunder, over, around, Administration, Department of Justice.
including those not listed in Section 1, is
and under the submerged underwater
subject to immediate temporary regulation. ACTION: Notice of intent.
cultural resources in Lake Michigan. The
An emergency regulation shall not take effect
eastern boundary of the sanctuary begins
approximately 9.5 miles east of the
without the approval of the Governor of SUMMARY: The Administrator of the Drug
Wisconsin or her/his designee or designated Enforcement Administration is issuing
Wisconsin shoreline in Lake Michigan
agency. this notice of intent to temporarily
roughly on the border between Manitowoc
and Kewaunee County. From this point the Article V: Relation to Other Regulatory schedule six synthetic cannabinoids:
boundary continues in Lake Michigan Programs Methyl 2-(1-(5-fluoropentyl)-1H-
roughly to the SSW until it intersects the Section 1. Fishing Regulations, Licenses, indazole-3-carboxamido)-3,3-
border between Ozaukee and Milwaukee and Permits. Fishing in the Sanctuary shall dimethylbutanoate [5F-ADB; 5F-MDMB-
County at a point approximately 13 miles not be regulated as part of the Sanctuary PINACA]; methyl 2-(1-(5-fluoropentyl)-
east of the shoreline. The southern boundary management regime authorized by the Act. 1H-indazole-3-carboxamido)-3-
continues west approximating the border However, fishing in the Sanctuary may be methylbutanoate [5F-AMB]; N-
between these same two counties until it regulated by other Federal, State, Tribal and
intersects the shoreline near Mequon, WI. (adamantan-1-yl)-1-(5-fluoropentyl)-1H-
local authorities of competent jurisdiction, indazole-3-carboxamide [5F-APINACA,
The western boundary continues north and designation of the Sanctuary shall have
following the shoreline for approximately 90 no effect on any regulation, permit, or license 5F-AKB48]; N-(1-amino-3,3-dimethyl-1-
miles cutting across the mouths of rivers and issued thereunder. oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-
streams; specifically those of Sauk Creek at Section 2. Other Regulations, Licenses, and indazole-3-carboxamide [ADB-
Port Washington, the Sheboygan River at Permits. If any valid regulation issued by any FUBINACA]; methyl 2-(1-
Sheboygan, Manitowoc Harbor as Federal, state, Tribal, or local authority of (cyclohexylmethyl)-1H-indole-3-
Manitowoc, and East Twin River at Two competent jurisdiction, regardless of when carboxamido)-3,3-dimethylbutanoate
Rivers as well as any other smaller streams issued, conflicts with a Sanctuary regulation, [MDMB-CHMICA, MMB-CHMINACA]
and creeks. The western boundary ends at the regulation deemed by the Director of the
roughly the border between Manitowoc and and methyl 2-(1-(4-fluorobenzyl)-1H-
Office of National Marine Sanctuaries,
Kewaunee County along the shoreline near National Oceanic and Atmospheric indazole-3-carboxamido)-3,3-
Twin Creeks, WI. The northern boundary Administration, or designee, in consultation dimethylbutanoate [MDMB-
continues from the shoreline east with the State of Wisconsin, to be more FUBINACA], into schedule I pursuant to
approximating the border between these protective of Sanctuary resources and the temporary scheduling provisions of
same two counties back to its point of origin qualities shall govern. Pursuant to section the Controlled Substances Act (CSA).
9.5 miles offshore. 304(c)(1) of the Act, 16 U.S.C. 1434(c)(1), no This action is based on a finding by the
valid lease, permit, license, approval, or Administrator that the placement of
Article III: Special Characteristics of the
other authorization issued by any Federal, these synthetic cannabinoids into
Area
State, Tribal, or local authority of competent
The historic shipwrecks in the Wisconsin- jurisdiction, or any right of subsistence use
schedule I of the Controlled Substances
Lake Michigan National Marine Sanctuary or access, may be terminated by the Secretary Act is necessary to avoid an imminent
are representative of vessels that sailed and of Commerce, or designee, as a result of this hazard to the public safety. Any final
steamed the Lake Michigan corridor, carrying designation, or as a result of any Sanctuary order will impose the administrative,
grain and raw materials east as other vessels regulation, if such lease, permit, license, civil, and criminal sanctions and
mstockstill on DSK3G9T082PROD with PROPOSALS
came west loaded with coal, manufactured approval, or other authorization, or right of regulatory controls applicable to
good, and immigrants. Eighteen of the 37 subsistence use or access was issued or in schedule I substances under the
shipwrecks are listed on the National existence as of the effective date of this Controlled Substances Act on the
Register of Historic Places. Many of the designation. However, the Secretary of
shipwrecks in the proposed sanctuary retain Commerce or designee, in consultation with
manufacture, distribution, possession,
an unusual degree of architectural integrity, the State of Wisconsin, may regulate the importation, exportation of, and
with 14 vessels virtually intact. Well exercise of such authorization or right research and conduct with, instructional
preserved by Lake Michigan’s cold, fresh consistent with the purposes for which the activities of these synthetic
water, the shipwrecks and related Sanctuary is designated. cannabinoids.
VerDate Sep<11>2014 17:29 Jan 06, 2017 Jkt 241001 PO 00000 Frm 00030 Fmt 4702 Sfmt 4702 E:\FR\FM\09JAP1.SGM 09JAP1](https://thefederalregister.org/doc/82_FR_2285/page/1.svg)
![Federal Register / Vol. 82, No. 5 / Monday, January 9, 2017 / Proposed Rules 2283
including dates of first encounter, identified in overdose and/or cases Conclusion
exhibits/reports, and locations. involving death attributed to their This notice of intent initiates a
5F-ADB: NFLIS—2,311 reports, first abuse. Adverse health effects reported temporary scheduling action and
encountered in September 2014, from these incidents involving 5F-ADB, provides the 30-day notice pursuant to
locations include: Arizona, Arkansas, 5F-AMB, 5F-APINACA, ADB- section 201(h) of the CSA, 21 U.S.C.
California, Florida, Georgia, Idaho, FUBINACA, MDMB-CHMICA and/or 811(h). In accordance with the
Indiana, Iowa, Kansas, Kentucky, MDMB-FUBINACA have included: provisions of section 201(h) of the CSA,
Louisiana, Missouri, New Jersey, North nausea, persistent vomiting, agitation, 21 U.S.C. 811(h), the Administrator
Dakota, Ohio, Oklahoma, Pennsylvania, altered mental status, seizures, considered available data and
South Carolina, Texas, Virginia, and
convulsions, loss of consciousness and/ information, herein sets forth the
Wisconsin.
5F-AMB: NFLIS—3,349 reports, first or cardio toxicity. Large clusters of grounds for his determination that it is
encountered in January 2014, locations overdoses requiring medical care have necessary to temporarily schedule
include: Arizona, Arkansas, California, been reported involving 5F-AMB, methyl 2-(1-(5-fluoropentyl)-1H-
Colorado, Florida, Georgia, Hawaii, MDMB-FUBINACA, MDMB-CHMICA indazole-3-carboxamido)-3,3-
Idaho, Illinois, Indiana, Iowa, Kansas, and 5F-ADB. Reported deaths involving dimethylbutanoate [5F-ADB; 5F-MDMB-
Kentucky, Louisiana, Maryland, these SCs have included 5F-ADB (8); PINACA]; methyl 2-(1-(5-fluoropentyl)-
Massachusetts, Minnesota, Mississippi, 5F-AMB (6); 5F-APINACA (1); ADB- 1H-indazole-3-carboxamido)-3-
Missouri, Nebraska, New Hampshire, FUBINACA (2); MDMB-CHMICA (4), methylbutanoate [5F-AMB]; N-
New Jersey, New Mexico, New York, European Monitoring Centre for Drugs (adamantan-1-yl)-1-(5-fluoropentyl)-1H-
North Dakota, Ohio, Oklahoma, Oregon, and Drug Addiction has reported an indazole-3-carboxamide [5F-APINACA,
Pennsylvania, South Carolina, additional 12 deaths involving MDMB- 5F-AKB48]; N-(1-amino-3,3-dimethyl-1-
Tennessee, Texas, Utah, Virginia, CHMICA; and MDMB-FUBINACA (1) oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-
Wisconsin, and Wyoming. (see factor 6 in ‘‘Supporting and Related indazole-3-carboxamide [ADB-
5F-APINACA: NFLIS—1,936 reports, Material’’). FUBINACA]; methyl 2-(1-
first encountered in August 2012, (cyclohexylmethyl)-1H-indole-3-
locations include: Alabama, Arizona, Finding of Necessity of Schedule I carboxamido)-3,3-dimethylbutanoate
Arkansas, California, Colorado, Placement To Avoid Imminent Hazard [MDMB-CHMICA, MMB-CHMINACA]
Connecticut, Florida, Georgia, Idaho, to Public Safety and methyl 2-(1-(4-fluorobenzyl)-1H-
Illinois, Indiana, Iowa, Kansas, indazole-3-carboxamido)-3,3-
In accordance with 21 U.S.C. dimethylbutanoate [MDMB-FUBINACA]
Kentucky, Louisiana, Maryland,
811(h)(3), based on the available data in schedule I of the CSA, and finds that
Minnesota, Mississippi, Missouri,
and information summarized above, the the placement of these substances into
Nebraska, New Hampshire, New Jersey,
continued uncontrolled manufacture, schedule I of the CSA on a temporary
North Dakota, Ohio, Oklahoma,
Pennsylvania, Puerto Rico, South distribution, importation, exportation, basis is necessary to avoid an imminent
Carolina, Tennessee, Texas, Utah, conduct of research and chemical hazard to the public safety.
Virginia, West Virginia, Wisconsin, and analysis, possession, and abuse of 5F- Because the Administrator hereby
Wyoming. ADB, 5F-AMB, 5F-APINACA, ADB- finds that it is necessary to temporarily
ADB-FUBINACA: NFLIS—942 FUBINACA, MDMB-CHMICA and place these SCs into schedule I to avoid
reports, first encountered in March MDMB-FUBINACA pose an imminent an imminent hazard to the public safety,
2014, locations include: Arkansas, hazard to the public safety. The DEA is any subsequent final order temporarily
California, Colorado, Florida, Georgia, not aware of any currently accepted scheduling these substances will be
Illinois, Indiana, Iowa, Kansas, medical uses for these substances in the effective on the date of publication in
Kentucky, Louisiana, Maryland, United States. A substance meeting the the Federal Register, and will be in
Mississippi, Missouri, New Jersey, New statutory requirements for temporary effect for a period of two years, with a
Mexico, New York, North Dakota, Ohio, scheduling, 21 U.S.C. 811(h)(1), may possible extension of one additional
Pennsylvania, Texas, Utah, Virginia, only be placed in schedule I. Substances year, pending completion of the regular
and Wyoming. in schedule I are those that have a high (permanent) scheduling process. 21
MDMB-CHMICA: NFLIS—227 reports, potential for abuse, no currently U.S.C. 811(h)(1) and (2). It is the
first encountered in March 2015, accepted medical use in treatment in the intention of the Administrator to issue
locations include: Arkansas, Georgia, United States, and a lack of accepted such a final order as soon as possible
Indiana, Kentucky, Louisiana, Nevada, after the expiration of 30 days from the
safety for use under medical
Ohio, Oklahoma, South Carolina, and date of publication of this notice. 5F-
supervision. Available data and
Texas. ADB, 5F-AMB, 5F-APINACA, ADB-
information for 5F-ADB, 5F-AMB, 5F-
MDMB-FUBINACA: NFLIS—507 FUBINACA, MDMB-CHMICA and
APINACA, ADB-FUBINACA, MDMB- MDMB-FUBINACA will then be subject
reports, first encountered in July 2015, CHMICA and MDMB-FUBINACA
locations include: Arkansas, California, to the regulatory controls and
indicate that these SCs have a high administrative, civil, and criminal
Colorado, Connecticut, Georgia, Idaho,
potential for abuse, no currently sanctions applicable to the manufacture,
Indiana, Kansas, Kentucky, Louisiana,
accepted medical use in treatment in the distribution, importation, exportation,
Missouri, Nevada, New Jersey, New
United States, and a lack of accepted research, conduct of instructional
Mexico, North Dakota, Ohio, Oklahoma,
mstockstill on DSK3G9T082PROD with PROPOSALS
Pennsylvania, Texas, Virginia, safety for use under medical activities, and chemical analysis and
Wisconsin, and West Virginia. supervision. As required by section possession of a schedule I controlled
201(h)(4) of the CSA, 21 U.S.C. substance.
Factor 6. What, if Any, Risk There Is to 811(h)(4), the Administrator, through a The CSA sets forth specific criteria for
the Public Health letter dated April 22, 2016, notified the scheduling a drug or other substance.
5F-ADB, 5F-AMB, 5F-APINACA, Assistant Secretary of the DEA’s Regular scheduling actions in
ADB-FUBINACA, MDMB-CHMICA and intention to temporarily place these six accordance with 21 U.S.C. 811(a) are
MDMB-FUBINACA have all been substances in schedule I. subject to formal rulemaking procedures
VerDate Sep<11>2014 17:29 Jan 06, 2017 Jkt 241001 PO 00000 Frm 00033 Fmt 4702 Sfmt 4702 E:\FR\FM\09JAP1.SGM 09JAP1](https://thefederalregister.org/doc/82_FR_2285/page/4.svg)
![2284 Federal Register / Vol. 82, No. 5 / Monday, January 9, 2017 / Proposed Rules
done ‘‘on the record after opportunity section 553 of the Administrative by Executive Order 12866 (Regulatory
for a hearing’’ conducted pursuant to Procedure Act (APA), 5 U.S.C. 553, do Planning and Review), section 3(f), and,
the provisions of 5 U.S.C. 556 and 557. not apply to this notice of intent. In the accordingly, this action has not been
21 U.S.C. 811. The regular scheduling alternative, even assuming that this reviewed by the Office of Management
process of formal rulemaking affords notice of intent might be subject to and Budget.
interested parties with appropriate section 553 of the APA, the This action will not have substantial
process and the government with any Administrator finds that there is good direct effects on the States, on the
additional relevant information needed cause to forgo the notice and comment relationship between the national
to make a determination. Final requirements of section 553, as any government and the States, or on the
decisions that conclude the regular further delays in the process for distribution of power and
scheduling process of formal issuance of temporary scheduling orders responsibilities among the various
rulemaking are subject to judicial would be impracticable and contrary to levels of government. Therefore, in
review. 21 U.S.C. 877. Temporary the public interest in view of the accordance with Executive Order 13132
scheduling orders are not subject to manifest urgency to avoid an imminent (Federalism) it is determined that this
judicial review. 21 U.S.C. 811(h)(6). hazard to the public safety. action does not have sufficient
Although the DEA believes this notice federalism implications to warrant the
Regulatory Matters of intent to issue a temporary preparation of a Federalism Assessment.
Section 201(h) of the CSA, 21 U.S.C. scheduling order is not subject to the
811(h), provides for an expedited notice and comment requirements of List of Subjects in 21 CFR Part 1308
temporary scheduling action where section 553 of the APA, the DEA notes Administrative practice and
such action is necessary to avoid an that in accordance with 21 U.S.C. procedure, Drug traffic control,
imminent hazard to the public safety. 811(h)(4), the Administrator will take Reporting and recordkeeping
As provided in this subsection, the into consideration any comments requirements.
Attorney General may, by order, submitted by the Assistant Secretary
schedule a substance in schedule I on a For the reasons set out above, the DEA
with regard to the proposed temporary
temporary basis. Such an order may not proposes to amend 21 CFR part 1308 as
scheduling order.
be issued before the expiration of 30 Further, the DEA believes that this follows:
days from (1) the publication of a notice temporary scheduling action is not a PART 1308—SCHEDULES OF
in the Federal Register of the intention ‘‘rule’’ as defined by 5 U.S.C. 601(2), CONTROLLED SUBSTANCES
to issue such order and the grounds and, accordingly, is not subject to the
upon which such order is to be issued, requirements of the Regulatory ■ 1. The authority citation for part 1308
and (2) the date that notice of the Flexibility Act (RFA). The requirements continues to read as follows:
proposed temporary scheduling order is for the preparation of an initial
transmitted to the Assistant Secretary. regulatory flexibility analysis in 5 U.S.C. Authority: 21 U.S.C. 811, 812, 871(b),
unless otherwise noted.
21 U.S.C. 811(h)(1). 603(a) are not applicable where, as here,
Inasmuch as section 201(h) of the the DEA is not required by section 553 ■ 2. In § 1308.11, add paragraph (h)(23)
CSA directs that temporary scheduling of the APA or any other law to publish through (28) to read as follows:
actions be issued by order and sets forth a general notice of proposed
the procedures by which such orders are rulemaking. § 1308.11 Schedule I
to be issued, the DEA believes that the Additionally, this action is not a * * * * *
notice and comment requirements of significant regulatory action as defined (h) * * *
(23) methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate, its optical, positional, and geometric isomers,
salts and salts of isomers (Other names: 5F-ADB; 5F-MDMB-PINACA) ........................................................................................... (7034)
(24) methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3-methylbutanoate, its optical, positional, and geometric isomers,
salts and salts of isomers (Other names: 5F-AMB) ............................................................................................................................ (7033)
(25) N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide, its optical, positional, and geometric isomers, salts and
salts of isomers (Other names: 5F-APINACA, 5F-AKB48) ................................................................................................................. (7049)
(26) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide, its optical, positional, and geometric
isomers, salts and salts of isomers (Other names: ADB-FUBINACA) ................................................................................................ (7010)
(27) methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate, its optical, positional, and geometric iso-
mers, salts and salts of isomers (Other names: MDMB-CHMICA, MMB-CHMINACA) ...................................................................... (7042)
(28) methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate, its optical, positional, and geometric isomers,
salts and salts of isomers (Other names: MDMB-FUBINACA) ........................................................................................................... (7020)
* * * * * DEPARTMENT OF LABOR ACTION:Request for information;
Dated: December 13, 2016. reopening of the comment period.
Mine Safety and Health Administration
Chuck Rosenberg, SUMMARY: In response to requests from
Acting Administrator. 30 CFR Parts 57, 70, 72, and 75 the public, the Mine Safety and Health
mstockstill on DSK3G9T082PROD with PROPOSALS
[FR Doc. 2017–00275 Filed 1–6–17; 8:45 am] Administration (MSHA) is reopening
[Docket No. MSHA–2014–0031]
BILLING CODE 4410–09–P the proposed rulemaking record for
RIN 1219–AB86 public comment on the Agency’s
request for information on Exposure of
Exposure of Underground Miners to Underground Miners to Diesel Exhaust.
Diesel Exhaust
DATES: The comment period for the
AGENCY:Mine Safety and Health request for information, published on
Administration, Labor. June 8, 2016 (81 FR 36826), and closed
VerDate Sep<11>2014 17:29 Jan 06, 2017 Jkt 241001 PO 00000 Frm 00034 Fmt 4702 Sfmt 4702 E:\FR\FM\09JAP1.SGM 09JAP1](https://thefederalregister.org/doc/82_FR_2285/page/5.svg)
Document Created: 2018-10-24 11:09:04
Document Modified: 2018-10-24 11:09:04
| Category | Regulatory Information | |
| Collection | Federal Register | |
| sudoc Class | AE 2.7: GS 4.107: AE 2.106: | |
| Publisher | Office of the Federal Register, National Archives and Records Administration | |
| Section | Proposed Rules | |
| Action | Notice of intent. | |
| Dates | January 9, 2017. | |
| Contact | Michael J. Lewis, Office of Diversion | |
| FR Citation | 82 FR 2280 | |
| CFR Associated | Administrative Practice and Procedure; Drug Traffic Control and Reporting and Recordkeeping Requirements |
2025 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR